Arrowhead Posts $1.36/Shr 3Q Loss, Wider Than Expected
ARWR has more than doubled off its 52-week low of $15.01.
Summary
Arrowhead Pharmaceuticals reported a fiscal 2026 third-quarter loss of $1.36 per share, wider than expected. The stock is trading near its 52-week high of $95.49, and the miss could trigger profit-taking. This follows recent positive pipeline news, including full enrollment in the pivotal Phase 3 YOSEMITE study for zodasiran and the acquisition of an FDA Priority Review Voucher. The earnings miss introduces a near-term headwind that may overshadow those catalysts. No revenue or guidance details were provided, leaving the full financial picture unclear until the company's filing or call.
At the time of this announcement, ARWR was trading at $93.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.6B. The 52-week trading range was $15.01 to $95.49. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.